Who owns ASCENDIS PHARMA A/S?
- CUSIP Number: 04351pad3
Tip: Access positions for across all investors
Analyze quarterly positions in Ascendis Pharma A/s with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Ascendis Pharma A/s stock
Who bought or sold ASCENDIS PHARMA A/S this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Linden Advisors | 137M | $195M | -5% | Dec 2025 |
|
| Wolverine Asset Management | 79M | $116M | 0% | Mar 2026 |
|
| DeepCurrents Investment Group | 50M | $73M | 49% | Mar 2026 |
|
| Point72 Asset Management | 48M | $71M | 139% | Mar 2026 |
|
| Franklin Resources | 47M | $70M | 0% | Mar 2026 |
|
| Capstone Investment Advisors | 35M | $51M | 35% | Mar 2026 |
|
| Lazard Asset Management | 14M | $205k | -60% | Mar 2026 |
|
| State Street Corporation | 12M | $18M | 2% | Dec 2025 |
|
| SSI Investment Management | 11M | $16M | 0% | Mar 2026 |
|
| Partner Fund Management | 11M | $15M | -7% | Dec 2025 |
|
| BlackRock | 9.2M | $14M | 26% | Mar 2026 |
|
| Ameriprise Financial | 7.0M | $10M | 8% | Mar 2026 |
|
| Nicholas Investments Partners | 6.0M | $8.5M | 0% | Dec 2025 |
|
| Polar Capital Holdings | 5.0M | $7.1M | 0% | Dec 2025 |
|
| Lombard Odier Asset Management | 4.2M | $5.9M | 1870% | Dec 2025 |
|
| DAFNA Capital Management | 4.0M | $5.9M | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 3.6M | $5.3M | 105% | Mar 2026 |
|
| Leucadia National Corporation | 3.5M | $5.2M | 123% | Mar 2026 |
|
| Bank of America Corporation | 3.1M | $4.5M | 100% | Mar 2026 |
|
| Balyasny Asset Management | 3.0M | $4.4M | 100% | Mar 2026 |
|
| State of Wisconsin Investment Board | 3.0M | $4.3M | 0% | Dec 2025 |
|
| Morgan Stanley | 2.9M | $4.2M | 100% | Mar 2026 |
|
| Invesco | 2.9M | $4.2M | -5% | Mar 2026 |
|
| Bnp Paribas Investment Partners | 2.0M | $2.8M | 0% | Dec 2025 |
|
| Wellington Management Company | 2.0M | $2.8M | 100% | Dec 2025 |
|
| Wells Fargo & Company | 1.8M | $2.7M | 424% | Mar 2026 |
|
| Barclays | 1.4M | $1.9M | 100% | Dec 2025 |
|
| Jane Street | 1.2M | $1.8M | 100% | Mar 2026 |
|
| Zazove Associates | 1.1M | $1.5M | 0% | Dec 2025 |
|
| Union Bancaire Privee, UBP SA | 820k | $1.0M | 58% | Mar 2026 |
|
| Central Pacific Bank - Trust Division | 458k | $672k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 425k | $623k | -65% | Mar 2026 |
|
| SG Americas Securities | 180k | $27M | 0% | Mar 2026 |
|
| Russell Investments | 101k | $150k | -44% | Mar 2026 |
|
| Virtus ETF Advisers | 60k | $88k | 88% | Mar 2026 |
|
| Loomis, Sayles and | 18k | $3.8M | 100% | Dec 2025 |
|
| Boussard & Gavaudan Investment Management | 8.5k | $12M | 100% | Dec 2025 |
|
| Oddo Bhf Asset Management Sas | 161.00 | $237k | 0% | Mar 2026 |
|
Who sold out of Ascendis Pharma A/s?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Tenor Capital Management | Dec 2025 | 21M | $30M |
| Davidson Kempner Capital Management | Dec 2025 | 10M | $14M |
| Ing Investment Management | Dec 2025 | 1.7M | $2.4M |
| Man Group | Dec 2025 | 1.2M | $1.6M |
| RWC Asset Management | Dec 2025 | 970k | $1.4M |
| Groupama Asset Managment | Dec 2025 | 700k | $987k |
| Oaktree Capital Management | Dec 2025 | 700k | $994k |
| Jpmorgan Chase & Co | Sep 2025 | 458k | $607k |
| Shenkman Capital Management | Dec 2025 | 439k | $626M |
| Deutsche Bank Aktiengesellschaft | Dec 2025 | 375k | $531k |
| Bank of New York Mellon | Dec 2025 | 200k | $279k |